missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human DNAH11 (aa 808-906) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (72%), Rat (72%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-84294 (PA5-84294. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
This gene encodes a ciliary outer dynein arm protein and is a member of the dynein heavy chain family. It is a microtubule-dependent motor ATPase and has been reported to be involved in the movement of respiratory cilia. Mutations in this gene have been implicated in causing Kartagener Syndrome (a combination of situs inversus totalis and Primary Ciliary Dyskinesia (PCD), also called Immotile Cilia Syndrome 1 (ICS1)) and male sterility. [provided by RefSeq, Mar 2013].
Specifications
Specifications
| Accession Number | Q96DT5 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 8701 |
| Name | Human DNAH11 (aa 808-906) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | axonemal beta dynein heavy chain 11; axonemal dynein heavy chain 11; CILD7; ciliary dynein heavy chain 11; DNAH11; DNAHBL; DNAHC11; DNHBL; DPL11; dynein axonemal heavy chain 11; dynein heavy chain 11, axonemal; dynein, axonemal, heavy chain 11; dynein, axonemal, heavy polypeptide 11; dynein, ciliary, heavy chain 11 |
| Common Name | DNAH11 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction